Medtronic Announces Retirement of EVP, Enterprise Operations Gregory L. Smith

Recently, Medtronic (Medtronic, NYSE: MDT) submitted a document to the U.S. Securities and Exchange Commission (SEC), confirmingGregory L. Smith, EVP, Enterprise Operations, to Retire on December 2, 2025According to the document, Smith informed the company of his retirement decision on November 1st. After leaving, he will join a private equity holding firm.

As the highest leader of Medtronic's global manufacturing and supply chain system, Smith has led the restructuring process of the company's "enterprise operations" over the past four years. The timing of his appointment was highly symbolic — in the spring of 2021, the global medical device industry was experiencing the most severe period of supply chain challenges: shortages of raw materials, limited chip supplies, and delays in cross-border logistics occurred one after another, presenting unprecedented challenges to Medtronic’s production and delivery systems.

Against this backdrop, Smith drove Medtronic to integrate its global production, procurement, and logistics systems into a unified management structure. His tenure is considered one of the key phases in Medtronic's transition from "multi-business collaboration" to "system centralization."

# Supply Chain Expert Crossover from Retail to Healthcare

Before joining Medtronic, Greg Smith had more than thirty years of cross-industry supply chain management experience.

He once served as the Executive Vice President of Walmart U.S. Supply Chain, leading the digitalization and cost optimization of the company's retail logistics network; prior to that, he held global operations or production management positions at Goodyear Tire, Conagra Foods, and Quaker Oats.

When Medtronic appointed him, they hoped to leverage his experience in the retail and manufacturing industries to introduce the operational logic of "high circulation efficiency, low inventory" into the medical device field. Compared with traditional manufacturing, the medical device industry chain is longer, the regulation is stricter, and the stocking cycle is more complex. How to improve system flexibility while ensuring quality became an important task during Smith's term.

# Term Review: From "Strategic Supplier" to Inventory Optimization

In his first public interview after taking office (2022), Smith explicitly stated that Medtronic's future supply chain would be "more centralized and streamlined," with the company focusing on a small number of strategic suppliers capable of long-term cooperation and innovation. He pointed out at the time,The overall inventory level in the medical device industry is relatively high. Improving the accuracy of planning and supply forecasting is a key link to enhancing global operational efficiency.

According to the interview at the time, Smith emphasized that Medtronic is advancing end-to-end integrated business planning, reducing in-transit inventory and working capital occupancy through more accurate demand signals and networked collaboration. During the same period, Medtronic CEO Geoff Martha also mentioned on an analyst call that the company "is reshaping its global operating system to build resilience that was previously lacking," and expressed approval of the reforms led by Smith.

In the following years,Medtronic Continues to Integrate Manufacturing Layout, Optimize Supplier System, and Establish a Unified Supply Chain Data Platform Internally, to strengthen visual management and risk response capabilities. Although the details of this series of work are rarely disclosed to the public, it can be seen from multiple public occasions that Medtronic has maintained a relatively stable delivery rhythm during the global supply chain volatility period.

# Conclusion

Greg Smith's retirement marks a milestone in Medtronic's "centralized supply chain" reform phase.
Over the past four years, Medtronic's adjustments to its global supply chain and corporate operations systems have gradually shifted from crisis response to structural optimization. For a medical technology company with global operations and a complex product portfolio, the efficiency of manufacturing and supply is no longer just a back-office function but a critical capability that directly determines whether innovations can be implemented and whether markets can respond.

The supply chain landscape of the global medical device industry is still evolving:叠加的地缘风险、成本压力与数字化转型促使企业在“韧性”与“效率”之间重新寻找平衡。

After Smith's departure, Medtronic is likely to continue in this direction, advancing the next phase of its global operational strategy under a more long-term systematic management approach.